复方α酮酸+缬沙坦联合扶正祛湿饮治疗Ⅲ～Ⅳ期慢性肾脏病的研究  

Study on compound α-ketoacid + valsartan combined with Fuzheng Qushi decoction in the treatment of stage Ⅲ-Ⅳ chronic kidney disease

作　　者：荆仕娟[1] 周伟[1] 张智敏[1] 张五星[1] 王昱景[1] 李杨[1] ING Shijuan;ZHOU Wei;ZHANG Zhimin;ZHANG Wuxing;WANG Yujing;LI Yang(The309 Hospital of the Chinese People's Liberation Army,Beijing 100091,China)

机构地区：[1]中国人民解放军第三0九医院,北京100091

出　　处：《现代中西医结合杂志》2019年第7期720-723,共4页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的探讨复方α酮酸+缬沙坦联合扶正祛湿饮治疗Ⅲ～Ⅳ期慢性肾脏病疗效及对相关炎症因子、氧化应激指标水平的影响。方法将150例Ⅲ～Ⅳ期慢性肾脏病患者随机分为2组,对照组75例给予复方α酮酸+缬沙坦治疗,观察组75例在对照组基础上加用扶正祛湿饮辅助治疗。统计2组治疗6个月后临床疗效和不良反应发生率,观察2组治疗前及治疗6个月后24 h尿蛋白定量、血肌酐(SCr)、尿素氮(BUN)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、转化生长因子β1(TGF-β1)水平及健康调查简表(SF-36)评分变化情况。结果观察组治疗后24 h尿蛋白定量、SCr、BUN、IL-6、TNF-α及TGF-β1水平均显著低于治疗前及对照组(P均<0. 05),SOD、GSH-Px水平及SF-36评分均显著高于治疗前及对照组(P均<0. 05);观察组临床疗效显著优于对照组(P <0. 05); 2组不良反应发生率比较差异无统计学意义(P>0. 05)。结论复方α酮酸+缬沙坦联合扶正祛湿饮治疗Ⅲ～Ⅳ期慢性肾脏病可有效控制相关症状体征,促进肾脏功能恢复,抑制机体炎症反应,调节SOD、GSH-Px及TGF-β1水平,且安全。Objective It is to investigate the curative effect of compound α-ketoacid+valsartan combined with Fuzheng Qushi decoction in the treatment of stage Ⅲ-Ⅳ chronic kidney disease and its influence on the levels of related inflammatory factors and oxidative stress.Methods 150 patients with stage Ⅲ-Ⅳ chronic kidney disease were randomly divided into 2 groups.75 patients in the control group were treated with compound α-ketoacid + valsartan.75 patients in the observation group were given Fuzheng Qushi decoction for assisted therapy based on the control group.The clinical efficacy and adverse reaction rate were assessed after 6 months of treatment.The changes of the levels of 24h urine protein quantitation,serum creatinine(SCr),urea nitrogen(BUN),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),superoxide dismutase(SOD),glutathione peroxidase(GSH-Px),transforming growth factor β1(TGF-β1)and the scores of Health Survey Summary(SF-36)were observed before and after 6 months of treatment.Results The levels of 24h urine protein quantitation,SCr,BUN,IL-6,TNF-α and TGF-β1 in the observation group after treatment were significantly lower while the levels of SOD,GSH-Px and SF-36 scores were significantly higher than those before treatment and in the control group after treatment(P<0.05).The clinical efficacy of the observation group was significantly better than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Compound α-ketoacid+valsartan combined with Fuzheng Qushi decoction can effectively control the symptoms and signs,prevent renal function recovery,inhibit the body's inflammatory response and regulate SOD,GSH-Px and TGFβ1 levels with good safety in the treatment of stage Ⅲ-Ⅳ chronic kidney disease.

关 键 词：复方Α酮酸 缬沙坦 扶正祛湿饮 慢性肾脏病 超氧化物歧化酶 

分 类 号：R692[医药卫生—泌尿科学]